Share this Article:

Related Articles:

The activity and tolerability of trabectedin has been widely studied in the second-line STS setting, but few studies evaluate it as first-line therapy for patients with comorbidities that preclude anthracycline-based chemotherapy. This study, TR1US, assessed the efficacy, tolerability, and pharmacokinetics [ Read More ]

In addition to pazopanib, other mechanistically similar antiangiogenic TKIs have been explored in sarcomas. Although pazopanib may possess unique properties that enhance its antisarcoma activity, this activity may be a general property of antiangiogenic TKIs or a reflection of pazopanib’s [ Read More ]